Business
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
Conference Call to be Held at 9:00am ET MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an
About this update from Summit Therapeutics Inc.
[{"type":"text","content":"\nConference Call to be Held at 9:00am ET\n\n\n MIAMI--(BUSINESS WIRE)--\nSummit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2024 financial results and provide an operational update for the Company on Tuesday, August 6, 2024, before the market opens.\n\n\nSummit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com. An archived edition of the session will be available on our website.\n\n\nAbout Ivonescimab\n\n\nIvonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, Japan, Latin America, including Mexico and all countries in Central America, South America, and the Caribbean, the Middle East, and Africa, and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.\n\n\nThis could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Ivonescimab’s tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME with over 18-fold increased binding affinity to PD-1 in the presence of VEGF in vitro, and over 4-times increased binding affinity to VEGF in the presence of PD-1 in vitro (Zhong, et al, SITC, 2023). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days (Zhong, et al, SITC, 2023), is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets.\n\n\nIvonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently enga...